- Home
- MTRX vs VNDA Comparison
MTRX vs VNDA Comparison
Compare MTRX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- VNDA
- Stock Information
- Founded
- MTRX 1984
- VNDA 2002
- Country
- MTRX United States
- VNDA United States
- Employees
- MTRX N/A
- VNDA N/A
- Industry
- MTRX Engineering & Construction
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MTRX Consumer Discretionary
- VNDA Health Care
- Exchange
- MTRX Nasdaq
- VNDA Nasdaq
- Market Cap
- MTRX 373.0M
- VNDA 261.7M
- IPO Year
- MTRX 1990
- VNDA 2006
- Fundamental
- Price
- MTRX $13.69
- VNDA $4.91
- Analyst Decision
- MTRX Strong Buy
- VNDA Strong Buy
- Analyst Count
- MTRX 1
- VNDA 3
- Target Price
- MTRX $20.00
- VNDA $15.33
- AVG Volume (30 Days)
- MTRX 187.8K
- VNDA 388.0K
- Earning Date
- MTRX 05-07-2025
- VNDA 07-30-2025
- Dividend Yield
- MTRX N/A
- VNDA N/A
- EPS Growth
- MTRX N/A
- VNDA N/A
- EPS
- MTRX N/A
- VNDA N/A
- Revenue
- MTRX $742,408,000.00
- VNDA $201,351,000.00
- Revenue This Year
- MTRX $9.98
- VNDA $16.86
- Revenue Next Year
- MTRX $20.42
- VNDA $39.78
- P/E Ratio
- MTRX N/A
- VNDA N/A
- Revenue Growth
- MTRX N/A
- VNDA 13.37
- 52 Week Low
- MTRX $8.61
- VNDA $3.81
- 52 Week High
- MTRX $15.75
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- MTRX 61.92
- VNDA 62.83
- Support Level
- MTRX $13.31
- VNDA $4.85
- Resistance Level
- MTRX $14.10
- VNDA $5.07
- Average True Range (ATR)
- MTRX 0.39
- VNDA 0.16
- MACD
- MTRX 0.02
- VNDA 0.02
- Stochastic Oscillator
- MTRX 74.37
- VNDA 76.81
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.